Hip Replacement
Also known as: Hip arthroplasty, Hip prosthesis
Methodology & AI Transparency ⓘ
Hip Replacement Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Hip replacement is surgery for people with severe hip damage.
- 2 Real-world patient consensus: Synonyms for Hip Replacement (M17.3): Hip arthroplasty, Hip prosthesis (Arthritis & Joints).
- 3 Typical cash cost range: Primary evaluation for Hip Replacement incorporates weight-bearing joint radiography [Hip Replacement M17.3] and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Hip Replacement: Serum Uric Acid in Hip Replacement (M17.3: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.3)) and hs-CRP & Erythrocyte in Hip Replacement (M17.3: Sedimentation Rate).
Ask our AI Specialists anything about Hip Replacement
What Is Hip Replacement?
Hip replacement is surgery for people with severe hip damage. The most common cause of damage is osteoarthritis . Osteoarthritis causes pain, swelling, and reduced motion in your joints. It can interfere with your daily activities. If other treatments such as physical therapy, pain medicines, and exercise haven't helped, hip replacement surgery might be an option for you. During a hip replacement operation, the surgeon removes damaged cartilage and bone from your hip joint and replaces them with new, man-made parts.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Hip Replacement (M17.3) involves articular hyaline cartilage in Hip Replacement (M17.3: proteoglycan degradation). Cross-referenced with NIH MeSH (Arthroplasty, Replacement, Hip), progression correlates with shifts in Serum Uric Acid in Hip Replacement (M17.3: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.3)).
Common Symptoms & Clinical Signs
- • Help your hip joint work better
- • Improve walking and other movements
- • Presentation of Hip Replacement (M17.3): activity-related deep aching in Hip Replacement (M17.3: joint pain in)
- • Secondary Hip Replacement clinical sign: brief morning joint in Hip Replacement (M17.3: stiffness)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Hip Replacement Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M17.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Hip Replacement (M17.3: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M17.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Hip Replacement (M17.3: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M17.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Hip Replacement M17.3] | Preserved joint-space width (M17.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Hip Replacement
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Accrufer (Ferric Maltol) Accrufer • RxCUI 2539949 | Parenteral Iron Replacement | 78% | $9.8880 | $ 640.00 /mo |
| Magnesium Sulfate Natural Epsom Salt, Epsom Salt • RxCUI 829762 | Calculi Dissolution Agent | 87% | $0.0039 | $ 8.66 /mo |
| Velaglucerase Alfa Vpriv • RxCUI 901808 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme | 90% | $1.5000 | $ 69.25 /mo |
| Monsels Solution (Ferric Subsulfate) Monsels Solution • RxCUI RXN-B48783112 | Parenteral Iron Replacement | 92% | $6.0970 | $ 447.48 /mo |
| Ferumoxytol Ferabright, Feraheme • RxCUI RXN-24338310-2314 | Parenteral Iron Replacement | 93% | $2.5000 | $ 109.75 /mo |
| Levothyroxine, Liothyronine Np Thyroid 30, Np Thyroid 15 • RxCUI 313387 | l-Thyroxine | 94% | $0.5134 | $ 29.29 /mo |
| Vpriv (Velaglucerase Alfa) Vpriv • RxCUI 901812 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme | 94% | $2.7500 | $ 206.50 /mo |
| Ferabright (Ferumoxytol) Ferabright • RxCUI RXN-B24338310 | Parenteral Iron Replacement | 83% | $1.1400 | $ 90.58 /mo |
| Testosterone Vogelxo, Natesto Nasal Gel • RxCUI 1599949 | Androgen | 74% | $0.5076 | $ 29.06 /mo |
| Venofer (Iron Sucrose) Venofer (Iron Sucrose) Generic • RxCUI RXN-516621568-2366 | Parenteral Iron Replacement | 90% | $12.2067 | $ 185.00 /mo |
| Ferric Subsulfate Monsels Solution • RxCUI RXN-48783112-2762 | Parenteral Iron Replacement | 93% | $6.0970 | $ 185.00 /mo |
| Testosterone Cypionate, Alcohol Testone Cik • RxCUI 797544 | FDA Prescription Therapeutic Agent | 86% | $2.1035 | $ 93.69 /mo |
| Injectafer (Ferric Carboxymaltose Injection) Injectafer • RxCUI RXN-B05170650 | Parenteral Iron Replacement | 81% | $6.0970 | $ 447.48 /mo |
| Infed (Iron Dextran) Infed • RxCUI 311144 | Parenteral Iron Replacement | 74% | $18.0002 | $ 640.00 /mo |
| Ferrlecit (Sodium Ferric Gluconate Complex) Ferrlecit • RxCUI 261123 | Parenteral Iron Replacement | 82% | $6.0970 | $ 447.48 /mo |
| Fludrocortisone Acetate Florinef • RxCUI 313979 | Pain & Inflammation Agent | 77% | $0.3098 | $ 12.45 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Hip Replacement)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
| New Insights on Effect of testosterone replacement therapy on lower urinary tract: What a 2,453-Participant Study Found The results demonstrate that TRT does not worsen LUTS regardless of the administration route. Journal of evidence-based medicine • 2024-09-15 • Meta-Analysis | N = 2,453 | 99/100 | PMID 39004879 ↗ |
| New Insights on Long-Term heart and blood vessel Safety of Testosterone-Replacement Therapy in: What a 9,280-Participant Study Found In men with low to low-normal testosterone, aged 40 and above, TRT did not increase all-cause mortality, heart and blood vessel mortality, stroke, or heart attack, but increased the incidence of cardiac arrhythmias. American journal of cardiovascular drugs : drugs, devices, and other interventions • 2025-11-15 • Meta-Analysis | N = 9,280 | 99/100 | PMID 40694252 ↗ |
| New Insights on Effect of testosterone replacement therapy on fracture risk in hypogonadal: What a 2,711-Participant Study Found TRT is associated with an increased incidence of predominantly non-major fractures, while the risk of major osteoporotic fractures, including hip and vertebral fractures, was not increased. Maturitas • 2026-06-15 • Meta-Analysis | N = 2,711 | 99/100 | PMID 42066666 ↗ |
| New Insights on Efficacy of testosterone replacement therapy for treating metabolic disturbances: What a 1,373-Participant Study Found This study demonstrated greater improvement in metabolic profiles for patients given TRT versus placebo. International urology and nephrology • 2021-09-15 • Meta-Analysis | N = 1,373 | 99/100 | PMID 34089171 ↗ |
Hip Replacement Patient Community & “People Like Me” Threads
Filter Hip Replacement community threads and patient logs by age, biological sex, dosage, and treatment duration.